無料レポート プレゼントキャンペーン 実施中 : メールサービスに新規登録いただいた方にご用意した無料レポートをご提供

株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

非侵襲性出生前検査(NIPT)の世界市場:検査、手法、プラットフォーム、用途、26カ国の分析、特許動向、競合環境 - 分析と予測(2018〜2028年)

Global Non-Invasive Prenatal Testing (NIPT) Market: Focus on Tests, Methods, Platforms, Applications, 26 Countries' Analysis, Patent Landscape and Competitive Landscape - Analysis and Forecast 2018-2028

発行 BIS Research Inc. 商品コード 731207
出版日 ページ情報 英文 406 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=114.61円で換算しております。
Back to Top
非侵襲性出生前検査(NIPT)の世界市場:検査、手法、プラットフォーム、用途、26カ国の分析、特許動向、競合環境 - 分析と予測(2018〜2028年) Global Non-Invasive Prenatal Testing (NIPT) Market: Focus on Tests, Methods, Platforms, Applications, 26 Countries' Analysis, Patent Landscape and Competitive Landscape - Analysis and Forecast 2018-2028
出版日: 2018年10月20日 ページ情報: 英文 406 Pages
概要

世界の非侵襲性出生前検査(NIPT)市場は2028年までに56億7,000万米ドルになると予測されています。遺伝子疾患の罹患率上昇と医療インフラの開発が、より良い診断と出生前ケアの改善にむけたNIPT導入を促進しています。

当レポートでは、世界の非侵襲性出生前検査(NIPT)市場について調査し、市場の現状と2028年までの成長予測、セグメント別動向、地域別動向、および市場に参入する企業のプロファイルなどをまとめています。

Figure Global NIPT Market

エグゼクティブサマリー

第1章 市場概要

第2章 市場動向

  • 概要
  • 影響分析
  • 市場促進因子
  • 市場阻害因子
  • 市場の機会

第3章 競合環境

  • イントロダクション
  • 発展と戦略
  • 市場シェア分析
  • 成長シェアマトリクス
  • 主なステークホルダー
  • 業界の魅力度

第4章 業界動向

  • イントロダクション
  • 特許分析
  • 臨床試験所改善修正プログラム
  • 規制当局リスト

第5章 NIPT市場:検査別

第6章 NIPT市場:手法別

第7章 NIPT市場:プラットフォーム別

第8章 NIPT市場:用途別

第9章 NIPT市場:地域別

  • 概要
  • 世界動向
  • 北米
  • 欧州
  • アジア太平洋地域
  • その他

第10章 企業プロファイル

第11章 レポートの範囲と方法

図表

List of Tables

  • 1 Global NIPT Market (2017 and 2028)
  • 2 Major Chromosomal Aneuploidies
  • 3 Incidence Rate of Major Chromosomal Aneuploidies
  • 4 Technological Approach for NIPT
  • 5 Impact Analysis of Market Dynamics
  • 6 List of Regulatory Authorities involved in CLIA Program
  • 7 List of Regulatory Bodies
  • 8 NIPT Market (by Test), 2017-2028, ($Million)
  • 9 NIPT Market (by Test), 2017-2028, (Units)
  • 10 North America NIPT Market (by Test), 2017-2028, ($Million)
  • 11 North America NIPT Market (by Test), 2017-2028, (Units)
  • 12 Europe NIPT Market (by Test), 2017-2028, ($Million)
  • 13 Europe NIPT Market (by Test), 2017-2028, (Units)
  • 14 Europe NIPT Market (by Country), 2017-2028, ($Million)
  • 15 Europe NIPT Market (by Country), 2017-2028, (Units)
  • 16 Asia-Pacific NIPT Market (by Test), 2017-2028, ($Million)
  • 17 Asia-Pacific NIPT Market (by Test), 2017-2028, (Units)
  • 18 Asia-Pacific NIPT Market (by Country), 2017-2028, ($Million)
  • 19 Asia-Pacific NIPT Market (by Country), 2017-2028, (Units)
  • 20 Rest-of-the-World NIPT Market (by Test), 2017-2028, ($Million)
  • 21 Rest-of-the-World NIPT Market (by Test), 2017-2028, (Units)

List of Figures

  • 1 Impact of Market Drivers and Market Restraints
  • 2 Market Statistics
  • 3 Global NIPT Market (by Test), $Million
  • 4 Global NIPT Market (by Test), Units
  • 5 Global NIPT Market (by Method), 2017
  • 6 Global NIPT Market (by Method), 2028
  • 7 Global NIPT Market (by Application), 2017
  • 8 Global NIPT Market (by Application), 2028
  • 9 Global NIPT Market Value (by Region), 2017 and 2028
  • 10 Global NIPT Market Volume (by Region), 2017 and 2028
  • 11 Global NIPT Market (by Region), 2017
  • 12 Global NIPT Market (by Region), 2028
  • 13 Prenatal Testing Timeline During Pregnancy
  • 14 Different Indications for NIPT
  • 15 NIPT Approach
  • 16 Benefits and Risks Associated with NIPT
  • 17 Ecosystem Players of Global Prenatal Testing Market
  • 18 Global Prenatal Testing Market: Opportunity Matrix
  • 19 Global NIPT Market Value (2017-2028)
  • 20 Global NIPT Market Volume (2017-2028)
  • 21 Competitive Landscape (January 2014-August 2018)
  • 22 Share of Key Developments and Strategies (January 2014-August 2018)
  • 23 Product Launch Share, by Companies
  • 24 Joint Ventures, Partnerships, and Collaborations Share, by Companies
  • 25 Market Share Analysis
  • 26 Growth Share Matrix (by Test), 2017
  • 27 Growth Share Matrix (by Region), 2017
  • 28 Porter's Five Forces Analysis
  • 29 Industry Insights (January 2014-August 2018)
  • 30 Patent Share (by Assignee)
  • 31 Classification of Tests in CLIA Program
  • 32 NIPT Market, by Test
  • 33 Global NIPT Market (by Verifi), by Revenue, 2017-2028
  • 34 Global NIPT Market (by Verifi), by Volume, 2017-2028
  • 35 Global NIPT Market (by MaterniT21 PLUS and MaterniT GENOME), by Revenue, 2017-2028
  • 36 Global NIPT Market (by MaterniT21 PLUS and MaterniT GENOME), by Volume, 2017-2028
  • 37 Global NIPT Market (by PrenaTest, GeneSafe, and PrenatalSAFE), by Revenue, 2017-2028
  • 38 Global NIPT Market (by PrenaTest, GeneSafe, and PrenatalSAFE), by Volume, 2017-2028
  • 39 Global NIPT Market (by Panorama), by Revenue, 2017-2028
  • 40 Global NIPT Market (by Panorama), by Volume, 2017-2028
  • 41 Global NIPT Market (by Qnatal Advanced), by Revenue, 2017-2028
  • 42 Global NIPT Market (by Qnatal Advanced), by Volume, 2017-2028
  • 43 Global NIPT Market (by Harmony), by Revenue, 2017-2028
  • 44 Global NIPT Market (by Harmony), by Volume, 2017-2028
  • 45 Global NIPT Market (by IONA), by Revenue, 2017-2028
  • 46 Global NIPT Market (by IONA), by Volume, 2017-2028
  • 47 Global NIPT Market (by NIFTY), by Revenue, 2017-2028
  • 48 Global NIPT Market (by NIFTY), by Volume, 2017-2028
  • 49 Global NIPT Market (by Bambni), by Revenue, 2017-2028
  • 50 Global NIPT Market (by Bambni), by Volume, 2017-2028
  • 51 Global NIPT Market (by Others), by Revenue, 2017-2028
  • 52 Global NIPT Market (by Others), by Volume, 2017-2028
  • 53 Global NIPT Market Share (by Method), 2017
  • 54 Global NIPT Market (by Method), by Revenue, 2017-2028
  • 55 Global NIPT Market (by Method), by Volume, 2017-2028
  • 56 Global NIPT Market (by cf-DNA), by Revenue, 2017-2028
  • 57 Global NIPT Market (by cf-DNA), by Volume, 2017-2028
  • 58 Global NIPT Market (by FCMB), by Revenue, 2017-2028
  • 59 Global NIPT Market (by FCMB), by Volume, 2017-2028
  • 60 Global NIPT Market Share (by Platform), 2017
  • 61 Global NIPT Market (by Platform), by Revenue, 2017-2028
  • 62 Global NIPT Market (by Platform), by Volume, 2017-2028
  • 63 Global NIPT Market (by NGS), by Revenue, 2017-2028
  • 64 Global NIPT Market (by NGS), by Volume, 2017-2028
  • 65 Global NIPT Market (by MPSS), by Revenue, 2017-2028
  • 66 Global NIPT Market (by MPSS), by Volume, 2017-2028
  • 67 Global NIPT Market (by Others), by Revenue, 2017-2028
  • 68 Global NIPT Market (by Others), by Volume, 2017-2028
  • 69 Global NIPT Market Share (by Application), 2017
  • 70 Global NIPT Market (by Application), by Revenue, 2017-2028
  • 71 Global NIPT Market (by Application), by Volume, 2017-2028
  • 72 Global NIPT Market (by Trisomy Detection), by Revenue, 2017-2028
  • 73 Global NIPT Market (by Trisomy Detection), by Volume, 2017-2028
  • 74 Global NIPT Market (by Microdeletion Detection), by Revenue, 2017-2028
  • 75 Global NIPT Market (by Microdeletion Detection), by Volume, 2017-2028
  • 76 Global NIPT Market (by Others), by Revenue, 2017-2028
  • 77 Global NIPT Market (by Others), by Volume, 2017-2028
  • 78 Global NIPT Market (by Region), by Revenue, 2017-2028
  • 79 Global NIPT Market (by Region), by Volume, 2017-2028
  • 80 Global NIPT Market Share, by Region (2017)
  • 81 Global NIPT Market Share, by Region (2028)
  • 82 North America NIPT Market, by Revenue, 2017-2028
  • 83 North America NIPT Market, by Volume, 2017-2028
  • 84 North America NIPT Market (by Country), by Revenue, 2017-2028
  • 85 North America NIPT Market (by Country), by Volume, 2017-2028
  • 86 The U.S. NIPT Market, by Revenue, 2017-2028
  • 87 The U.S. NIPT Market, by Volume, 2017-2028
  • 88 Canada NIPT Market, by Revenue, 2017-2028
  • 89 Canada NIPT Market, by Volume, 2017-2028
  • 90 Europe NIPT Market, by Revenue, 2017-2028
  • 91 Europe NIPT Market, by Volume, 2017-2028
  • 92 The U.K. NIPT Market, by Revenue, 2017-2028
  • 93 The U.K. NIPT Market, by Volume, 2017-2028
  • 94 Germany NIPT Market, by Revenue, 2017-2028
  • 95 Germany NIPT Market, by Volume, 2017-2028
  • 96 France NIPT Market, by Revenue, 2017-2028
  • 97 France NIPT Market, by Volume, 2017-2028
  • 98 Italy NIPT Market, by Revenue, 2017-2028
  • 99 Italy NIPT Market, by Volume, 2017-2028
  • 100 Spain NIPT Market, by Revenue, 2017-2028
  • 101 Spain NIPT Market, by Volume, 2017-2028
  • 102 The Netherlands NIPT Market, by Revenue, 2017-2028
  • 103 The Netherlands NIPT Market, by Volume, 2017-2028
  • 104 Belgium NIPT Market, by Revenue, 2017-2028
  • 105 Belgium NIPT Market, by Volume, 2017-2028
  • 106 Switzerland NIPT Market, by Revenue, 2017-2028
  • 107 Switzerland NIPT Market, by Volume, 2017-2028
  • 108 Sweden NIPT Market, by Revenue, 2017-2028
  • 109 Sweden NIPT Market, by Volume, 2017-2028
  • 110 Denmark NIPT Market, by Revenue, 2017-2028
  • 111 Denmark NIPT Market, by Volume, 2017-2028
  • 112 Poland NIPT Market, by Revenue, 2017-2028
  • 113 Poland NIPT Market, by Volume, 2017-2028
  • 114 Russia NIPT Market, by Revenue, 2017-2028
  • 115 Russia NIPT Market, by Volume, 2017-2028
  • 116 Rest-of-Europe NIPT Market, by Revenue, 2017-2028
  • 117 Rest-of-Europe NIPT Market, by Volume, 2017-2028
  • 118 Asia-Pacific NIPT Market, by Revenue, 2017-2028
  • 119 Asia-Pacific NIPT Market, by Volume, 2017-2028
  • 120 China NIPT Market, by Revenue, 2017-2028
  • 121 China NIPT Market, by Volume, 2017-2028
  • 122 Japan NIPT Market, by Revenue, 2017-2028
  • 123 Japan NIPT Market, by Volume, 2017-2028
  • 124 Australia NIPT Market, by Revenue, 2017-2028
  • 125 Australia NIPT Market, by Volume, 2017-2028
  • 126 India NIPT Market, by Revenue, 2017-2028
  • 127 India NIPT Market, by Volume, 2017-2028
  • 128 Singapore NIPT Market, by Revenue, 2017-2028
  • 129 Singapore NIPT Market, by Volume, 2017-2028
  • 130 Hong Kong NIPT Market, by Revenue, 2017-2028
  • 131 Hong Kong NIPT Market, by Volume, 2017-2028
  • 132 Malaysia NIPT Market, by Revenue, 2017-2028
  • 133 Malaysia NIPT Market, by Volume, 2017-2028
  • 134 Indonesia NIPT Market, by Revenue, 2017-2028
  • 135 Indonesia NIPT Market, by Volume, 2017-2028
  • 136 Vietnam NIPT Market, by Revenue, 2017-2028
  • 137 Vietnam NIPT Market, by Volume, 2017-2028
  • 138 South Korea NIPT Market, by Revenue, 2017-2028
  • 139 South Korea NIPT Market, by Volume, 2017-2028
  • 140 Philippines NIPT Market, by Revenue, 2017-2028
  • 141 Philippines NIPT Market, by Volume, 2017-2028
  • 142 Thailand NIPT Market, by Revenue, 2017-2028
  • 143 Thailand NIPT Market, by Volume, 2017-2028
  • 144 Rest-of-Asia-Pacific NIPT Market, by Revenue, 2017-2028
  • 145 Rest-of-Asia-Pacific NIPT Market, by Volume, 2017-2028
  • 146 Rest-of-the-World NIPT Market, by Revenue, 2017-2028
  • 147 Rest-of-the-World NIPT Market, by Volume, 2017-2028
  • 148 Share of Key Company Profiles (by Company Type)
  • 149 Agilent Technologies, Inc.: Overall Product Portfolio
  • 150 Agilent Technologies, Inc.: Product Portfolio for Global NIPT Market
  • 151 Agilent Technologies, Inc.: Overall Financials (2015-2017)
  • 152 Agilent Technologies, Inc.: Revenue by Business Segments (2015-2017)
  • 153 Agilent Technologies, Inc.: Revenue by Region (2015-2017)
  • 154 Agilent Technologies, Inc.: SWOT Analysis
  • 155 Annoroad Gene Technology: Overall Product Portfolio
  • 156 Annoroad Gene Technology: Product Portfolio for Global NIPT Market
  • 157 Annoroad Gene Technology: SWOT Analysis
  • 158 Berry Genomics Co., Ltd.: Overall Product Portfolio
  • 159 Berry Genomics Co., Ltd.: Product Portfolio for Global NIPT Market
  • 160 Berry Genomics Co., Ltd.: SWOT Analysis
  • 161 BGI Diagnosis: Overall Product Portfolio
  • 162 BGI Diagnosis: Product Portfolio for Global NIPT Market
  • 163 BGI Diagnosis: SWOT Analysis
  • 164 Centogene AG: Overall Product Portfolio
  • 165 Centogene AG: Product Portfolio for Global NIPT Market
  • 166 Centogene AG: SWOT Analysis
  • 167 Myriad Genetics, Inc.: Overall Product Portfolio
  • 168 Myriad Genetics, Inc.: Product Offerings for Global NIPT Market
  • 169 Myriad Genetics, Inc.: Overall Financials (2015-2017)
  • 170 Myriad Genetics, Inc.: Net Revenue by Business Segment (2015-2017)
  • 171 Myriad Genetics, Inc.: SWOT Analysis
  • 172 Eurofins Scientific: Overall Product Portfolio
  • 173 Eurofins Scientific: Product Offerings for Global NIPT Market
  • 174 Eurofins Scientific: Overall Financials (2015-2017)
  • 175 Eurofins Scientific: Net Revenue by Region (2015-2017)
  • 176 Eurofins Scientific: SWOT Analysis
  • 177 F. Hoffmann-La Roche AG: Overall Product Portfolio
  • 178 F. Hoffmann-La Roche AG: Product Portfolio for Global NIPT Market
  • 179 F. Hoffmann-La Roche AG: Overall Financials (2015-2017)
  • 180 F. Hoffmann-La Roche AG: Net Revenue by Business Segment (2015-2017)
  • 181 F. Hoffmann-La Roche AG: Net Revenue by Diagnostics Sub-division (2015-2017)
  • 182 F. Hoffmann-La Roche AG: Net Revenue by Region (2015-2017)
  • 183 F. Hoffmann-La Roche AG: SWOT Analysis
  • 184 Illumina, Inc.: Overall Product Portfolio
  • 185 Illumina, Inc.: Product Offerings for Global NIPT Market
  • 186 Illumina, Inc.: Overall Financials (2015-2017)
  • 187 Illumina, Inc.: Net Revenue by Business Segment (2015-2017)
  • 188 Illumina, Inc.: Net Revenue by Region (2015-2017)
  • 189 Illumina, Inc.: SWOT Analysis
  • 190 Natera, Inc.: Overall Product Portfolio
  • 191 Natera, Inc.: Product Offerings for Global NIPT Market
  • 192 Natera, Inc.: Overall Financials (2015-2017)
  • 193 Natera, Inc.: Revenue by Region (2015-2017)
  • 194 Natera, Inc.: SWOT Analysis
  • 195 Next Biosciences: Overall Product Portfolio
  • 196 Next Biosciences: Product Portfolio for Global NIPT Market
  • 197 Next Biosciences: SWOT Analysis
  • 198 NIPD Genetics: Overall Product Portfolio
  • 199 NIPD Genetics: Product Portfolio for Global NIPT Market
  • 200 NIPD Genetics : SWOT Analysis
  • 201 PerkinElmer, Inc.: Overall Product Portfolio
  • 202 PerkinElmer, Inc.: Product Portfolio for Global NIPT Market
  • 203 PerkinElmer, Inc.: Overall Financials (2015-2017)
  • 204 PerkinElmer, Inc.: Net Revenue by Business Segment (2015-2017)
  • 205 PerkinElmer, Inc.: Net Revenue by Region (2015-2017)
  • 206 PerkinElmer, Inc.: SWOT Analysis
  • 207 Premaitha Health Plc: Overall Product Portfolio
  • 208 Premaitha Health Plc: Product Portfolio for Global NIPT Market
  • 209 Premaitha Health: Overall Financials (2015-2017)
  • 210 Premaitha Health: Net Revenue by Region (2015-2017)
  • 211 Premaitha Health Plc: SWOT Analysis
  • 212 Quest Diagnostics Incorporated: Overall Product Portfolio
  • 213 Quest Diagnostics Incorporated: Product Portfolio for Global NIPT Market
  • 214 Quest Diagnostics Incorporated: Overall Financials (2015-2017)
  • 215 Quest Diagnostics Incorporated: Net Revenue by Business Segment (2015-2017)
  • 216 Quest Diagnostics Incorporated: Net Revenue by DIS Segment (2015-2017)
  • 217 Quest Diagnostics Incorporated: SWOT Analysis
  • 218 Laboratory Corporation of America Holdings : Overall Product Portfolio
  • 219 Laboratory Corporation of America Holdings: Product Offerings for Global NIPT Market
  • 220 Laboratory Corporation of America Holdings: Overall Financials (2015-2017)
  • 221 Laboratory Corporation of America Holdings: Net Revenue by Business Segment (2015-2017)
  • 222 Laboratory Corporation of America Holdings: Net Revenue by Region (2015-2017)
  • 223 Laboratory Corporation of America Holdings: SWOT Analysis
  • 224 Global NIPT Market Segmentation
  • 225 Considered Factors for Data Prediction and Modeling
目次
Product Code: BH017F

Global Non-Invasive Prenatal Testing (NIPT) Market to Deliver $5.67 Billion with 7,591,792 Units by 2028, Reports BIS Research

The life science industry is focused on the development of advanced NIPT tests using genome sequencing technologies for the early detection of genetic disorders. The increasing prevalence of genetic disorders and development of the healthcare infrastructure are promoting the adoption of the NIPT for better diagnosis and improved prenatal care.

Non-invasive prenatal testing (NIPT) is a sophisticated method used for the screening of chromosomal abnormalities developing in the fetus. Currently, NIPT is considered as a valuable test for the pregnant women to provide cost-effective and highly efficient early diagnosis of genetic disorders. Moreover, advancements in genome sequencing technologies reduce turnaround time and the complexity of diagnosis with next generation sequencing (NGS). The NGS technology provides several opportunities to develop the non-invasive diagnostic procedures for an early and accurate detection of various genetic disorders. The life science industry is witnessing significant growth of NIPT tests developed using the NGS technology. Several biotechnology companies are now indulging in the research and development of such NGS-based NIPT products. Furthermore, the advent of genome sequencing technologies in the life science industry has enabled the companies to detect the genetic diseases at an early stage and provide accurate results to remain competitive in the market.

The purpose of this study is to gain a holistic view of the NIPT market in terms of various influencing factors, such as recent trends, regulatory requirements, and technological advancements of the market. The scope of this report constitutes a detailed study of the tests associated with the global NIPT market across different regions. The market has been segmented into 'tests,' 'methods,' 'platforms,' 'applications,' and 'regions.' The report presents the reader with an opportunity to unlock comprehensive insights with respect to the market and helps in forming well-informed strategic decisions. The research uncovers some of the substantial parameters that must be taken into consideration before entering the market.

This research report aims at answering various aspects of the global NIPT market with the help of the key factors driving the market, restraints, and challenges that can inhibit the overall market growth and the current growth opportunities that are going to shape the future trajectory of the market expansion. The report includes an in-depth examination of the key players and recent developments taking place in this market. Moreover, the report includes chapters on market dynamics (market drivers, opportunities, and challenges) and industry analysis as well.

The research study highlights the factors governing the industry attractiveness with Porter's Five Forces for a comprehensive understanding of the global NIPT market. Moreover, the study includes detailed product mapping with further sub-segmentation in various countries, and in each sub-segment, the key market trends, list of the key companies, and the key strategies and developments have also been discussed.

The answers to the following key questions can be derived from this report:

  • How did the NIPT market evolve, and what is its scope in the future?
  • What are the major market drivers, challenges, and opportunities in the global NIPT market?
  • What are the key developmental strategies that are implemented by the key players to sustain in this market?
  • How the influencing factors will affect the industry attractiveness?
  • How NIPT is utilized for the detection of chromosomal abnormalities?
  • How investments by public and private companies and government organizations will affect the global NIPT market?
  • What was the market size of the leading segments and sub-segments of the global NIPT market in 2017?
  • How will the industry evolve during the forecast period 2018-2028?
  • What will be the growth rate of the NIPT during the forecast period?
  • How will each segment of the global NIPT market grow during the forecast period, and what will be the revenue generated by each of the segments by the end of 2028?
  • Which test segment, and application segment is expected to register the highest CAGR for the NIPT market?
  • What is the market size of NIPT in different countries of the world?
  • Which geographical region will contribute to the highest sales of NIPT?
  • Who are the key players in the NIPT market, and what are their contributions?

The key players who have been contributing significantly to the NIPT market include Agilent Technologies, Inc., Annoroad Gene Technology, Berry Genomics Co., Ltd., BGI Diagnosis, Centogene AG, Counsyl, Inc., Eurofins Scientific, F. Hoffmann-La Roche AG, Illumina, Inc., Laboratory Corporation of America Holdings, Natera, Inc., Next Biosciences, NIPD Genetics, PerkinElmer, Inc., Premaitha Health Plc, and Quest Diagnostics Incorporated, among others.

Executive Summary

Non-invasive prenatal testing (NIPT) is a sophisticated method used for the screening of chromosomal abnormalities developing in the fetus. It is a novel genetic screening method based on the analysis of cell-free fetal deoxyribose nucleic acid (cff-DNA) in the maternal plasma. The genetic screening is performed between 10-22 weeks of time frame, with small amount of blood sample and requires a minimum of 10 weeks of pregnancy for apt results. It is commercializing at a rapid pace due to emerging technologies for non-invasive analysis of the fetal genome, thus reducing the cost-effectiveness of NIPT. The exponential growth of the NIPT market is supported by various factors, such as reimbursement policies, insurance coverage, high incidence rate of Down syndrome, no risk of miscarriage with NIPT, and shifting trend toward child birth at an advanced maternal age (35 years or above).

Since the past few years (2011-2017), prenatal genetic testing has come up with new innovative and non-invasive technologies and testing options. However, it has been a challenge for women's healthcare providers to keep up with the swarm of publications and provide patients with the most accurate information regarding prenatal testing. Since a decade, researchers, physicians, and even pregnant women have been observing the benefits of a non-invasive tests that could potentially replace amniocentesis and chorionic villus sampling (CVS), and minimize the false positive results generated by them. Hence, with the advent of NIPT, there has been a reduction in the number of women undergoing highly invasive procedures.

The purpose of the study is to gain a holistic view of the NIPT market in terms of various factors influencing it such as recent trends and technological advancements of the market. The scope of this report is centered upon conducting a detailed study of the tests associated with the global NIPT market across different regions. The global NIPT market is segmented into five different parts namely by tets, by method, by platform, by application, and by region. The global market value and volume was estimated using these three different approaches and was validated with one another. The global NIPT market is expected to reach $5.67 billion with 7,591,792 units by 2028.

With the increasing demand for technological advancements in NIPT across various segments of the NIPT, the NIPT market is expected to witness rapid growth in the future. Further, the increasing insurance coverage and reimburesement policies in the developed markets such as the U.S., Japan, Germany, and the U.K. is the key driver for the growth of the NIPT market. Moreover, the Panorama test dominated the global NIPT market in 2017 among different commercialized tests. However, the IONA test is anticipated to witness the highest CAGR during the forecast period. The trisomy detection application of NIPT witnessed the highest industry demand. Further, the NGS platform for NIPT is also expected to witness impressive CAGR during the forecast period.

On the basis of regions, the global NIPT market is segmented into North America, Europe, Asia-Pacific, and Rest-of-the-World (RoW). North America is the leading contributor to the global NIPT market and contributed 51.55% and 52.31% in terms of revenue and volume respectively to the global market in 2017. However, Asia-Pacific is expected to grow at a CAGR of 18.01% and 19.13% in terms of revenue and volume respectively during the forecast period.

The key players who have been contributing significantly to the NIPT market include Agilent Technologies, Inc., Annoroad Gene Technology, Berry Genomics Co., Ltd., BGI Diagnosis, Centogene AG, Counsyl, Inc., Eurofins Scientific, F. Hoffmann-La Roche AG, Illumina, Inc., Laboratory Corporation of America Holdings, Natera, Inc., Next Biosciences, NIPD Genetics, PerkinElmer, Inc., Premaitha Health Plc, and Quest Diagnostics Incorporated, among others.

Table of Contents

Executive Summary

1 Market Overview

  • 1.1 Introduction
  • 1.2 NIPT Approach
  • 1.3 Different Methods of NIPT
  • 1.4 Benefits and Risks Associated with NIPT
  • 1.5 Technological Advancements
  • 1.6 World Economic Outlook of Prenatal Testing Market, 2017
  • 1.7 Global NIPT Market Scenario
  • 1.8 Assumptions and Limitations for Market Size Calculations

2 Market Dynamics

  • 2.1 Overview
  • 2.2 Impact Analysis
  • 2.3 Market Drivers
  • 2.4 Market Restraints
  • 2.5 Market Opportunities

3 Competitive Landscape

  • 3.1 Introduction
  • 3.2 Key Developments and Strategies
    • 3.2.1 Product Launches and Enhancements
    • 3.2.2 Joint Ventures, Partnerships, and Collaborations
    • 3.2.3 Mergers and Acquisitions
    • 3.2.4 Business Expansions, Awards, Recognitions, Certifications, and Others
  • 3.3 Market Share Analysis
  • 3.4 Growth Share Matrix (by Test), 2017
  • 3.5 Growth Share Matrix (by Region), 2017
  • 3.6 Key Stakeholders of NIPT Market
  • 3.7 Industry Attractiveness
    • 3.7.1 Bargaining Power of Suppliers
    • 3.7.2 Bargaining Power of Buyers
    • 3.7.3 Threat of New Entrants
    • 3.7.4 Threat of Substitute Products
    • 3.7.5 Intensity of Competitive Rivalry

4 Industry Insights

  • 4.1 Introduction
  • 4.2 Patent Analysis
  • 4.3 Clinical Laboratory Improvement Amendments (CLIA) Program
  • 4.4 List of Regulatory Bodies

5 Global Non-Invasive Prenatal Testing (NIPT) Market (by Test)

  • 5.1 Overview
  • 5.2 Verifi
  • 5.3 MaterniT21 PLUS and MaterniT GENOME
  • 5.4 PrenaTest, GeneSafe, and PrenatalSAFE
  • 5.5 Panorama
  • 5.6 Qnatal Advanced
  • 5.7 Harmony
  • 5.8 IONA
  • 5.9 NIFTY
  • 5.10 Bambni
  • 5.11 Others

6 Global Non-Invasive Prenatal Testing (NIPT) Market (by Method)

  • 6.1 Overview
  • 6.2 cf-DNA
  • 6.3 FCMB

7 Global Non-Invasive Prenatal Testing (NIPT) Market (by Platform)

  • 7.1 Overview
  • 7.2 NGS
  • 7.3 MPSS
  • 7.4 Others

8 Global Non-Invasive Prenatal Testing (NIPT) Market (by Application)

  • 8.1 Overview
  • 8.2 Trisomy Detection
  • 8.3 Microdeletion Detection
  • 8.4 Others

9 Global Non-Invasive Prenatal Testing (NIPT) Market (by Region)

  • 9.1 Overview
  • 9.2 Global Insights
  • 9.3 North America
    • 9.3.1 North America Market Dynamics
    • 9.3.2 North America Market (by Country)
      • 9.3.2.1 The U.S.
      • 9.3.2.2 Canada
  • 9.4 Europe
    • 9.4.1 Europe Market Dynamics
    • 9.4.2 Europe Market (by Country)
      • 9.4.2.1 The U.K.
      • 9.4.2.2 Germany
      • 9.4.2.3 France
      • 9.4.2.4 Italy
      • 9.4.2.5 Spain
      • 9.4.2.6 The Netherlands
      • 9.4.2.7 Belgium
      • 9.4.2.8 Switzerland
      • 9.4.2.9 Sweden
      • 9.4.2.10 Denmark
      • 9.4.2.11 Poland
      • 9.4.2.12 Russia
      • 9.4.2.13 Rest-of-Europe
  • 9.5 Asia-Pacific
    • 9.5.1 Asia-Pacific Market Dynamics
    • 9.5.2 Asia-Pacific (by Country)
      • 9.5.2.1 China
      • 9.5.2.2 Japan
      • 9.5.2.3 Australia
      • 9.5.2.4 India
      • 9.5.2.5 Singapore
      • 9.5.2.6 Hong Kong
      • 9.5.2.7 Malaysia
      • 9.5.2.8 Indonesia
      • 9.5.2.9 Vietnam
      • 9.5.2.10 South Korea
      • 9.5.2.11 Philippines
      • 9.5.2.12 Thailand
      • 9.5.2.13 Rest-of-Asia-Pacific
  • 9.6 Rest-of-the-World

10 Company Profiles

  • 10.1 Overview
  • 10.2 Agilent Technologies, Inc.
    • 10.2.1 Overview
    • 10.2.2 Corporate Summary
    • 10.2.3 Product Offerings for Global NIPT Market
    • 10.2.4 Financials
      • 10.2.4.1 Financial Summary
    • 10.2.5 SWOT Analysis
  • 10.3 Annoroad Gene Technology
    • 10.3.1 Overview
    • 10.3.2 Corporate Summary
    • 10.3.3 Product Offerings for Global NIPT Market
    • 10.3.4 SWOT Analysis
  • 10.4 Berry Genomics Co., Ltd.
    • 10.4.1 Overview
    • 10.4.2 Corporate Summary
    • 10.4.3 Product Offerings for Global NIPT Market
    • 10.4.4 SWOT Analysis
  • 10.5 BGI Diagnosis
    • 10.5.1 Overview
    • 10.5.2 Corporate Summary
    • 10.5.3 Product Offerings for Global NIPT Market
    • 10.5.4 SWOT Analysis
  • 10.6 Centogene AG
    • 10.6.1 Overview
    • 10.6.2 Corporate Summary
    • 10.6.3 Product Offerings for Global NIPT Market
    • 10.6.4 SWOT Analysis
  • 10.7 Counsyl, Inc. (Subsidiary of Myriad Genetics, Inc.)
    • 10.7.1 Overview
  • 10.8 Myriad Genetics, Inc.
    • 10.8.1 Overview
    • 10.8.2 Corporate Summary
    • 10.8.3 Product Offerings for Global NIPT Market
    • 10.8.4 Financials
      • 10.8.4.1 Financial Summary
    • 10.8.5 SWOT Analysis
  • 10.9 LifeCodexx AG (Subsidiary of Eurofins Scientific)
    • 10.9.1 Overview
  • 10.10 EUROFINS Genoma Group (Subsidiary of Eurofins Scientific)
    • 10.10.1 Overview
  • 10.11 Eurofins Scientific
    • 10.11.1 Overview
    • 10.11.2 Corporate Summary
    • 10.11.3 Product Offerings for Global NIPT Market
    • 10.11.4 Financials
      • 10.11.4.1 Financial Summary
    • 10.11.5 SWOT Analysis
  • 10.12 F. Hoffmann-La Roche AG
    • 10.12.1 Overview
    • 10.12.2 Corporate Summary
    • 10.12.3 Product Offerings for Global NIPT Market
    • 10.12.4 Financials
      • 10.12.4.1 Financial Summary
    • 10.12.5 SWOT Analysis
  • 10.13 Illumina, Inc.
    • 10.13.1 Overview
    • 10.13.2 Corporate Summary
    • 10.13.3 Product Offerings for Global NIPT Market
    • 10.13.4 Financials
      • 10.13.4.1 Financial Summary
    • 10.13.5 SWOT Analysis
  • 10.14 Natera, Inc.
    • 10.14.1 Overview
    • 10.14.2 Corporate Summary
    • 10.14.3 Product Offerings for Global NIPT Market
    • 10.14.4 Financials
      • 10.14.4.1 Financial Summary
    • 10.14.5 SWOT Analysis
  • 10.15 Next Biosciences
    • 10.15.1 Overview
    • 10.15.2 Corporate Summary
    • 10.15.3 Product Offerings for Global NIPT Market
    • 10.15.4 SWOT Analysis
  • 10.16 NIPD Genetics
    • 10.16.1 Overview
    • 10.16.2 Corporate Summary
    • 10.16.3 Product Offerings for Global NIPT Market
    • 10.16.4 SWOT Analysis
  • 10.17 PerkinElmer, Inc.
    • 10.17.1 Overview
    • 10.17.2 Corporate Summary
    • 10.17.3 Product Offerings for Global NIPT Market
    • 10.17.4 Financials
      • 10.17.4.1 Financial Summary
    • 10.17.5 SWOT Analysis
  • 10.18 Premaitha Health Plc
    • 10.18.1 Overview
    • 10.18.2 Corporate Summary
    • 10.18.3 Product Offerings for Global NIPT Market
    • 10.18.4 Financials
      • 10.18.4.1 Financial Summary
    • 10.18.5 SWOT Analysis
  • 10.19 Quest Diagnostics Incorporated
    • 10.19.1 Overview
    • 10.19.2 Corporate Summary
    • 10.19.3 Product Offerings for Global NIPT Market
    • 10.19.4 Financials
      • 10.19.4.1 Financial Summary
    • 10.19.5 SWOT Analysis
  • 10.20 Sequenom, Inc. (Subsidiary of Laboratory Corporation of America Holdings)
    • 10.20.1 Overview
  • 10.21 Laboratory Corporation of America Holdings
    • 10.21.1 Overview
    • 10.21.2 Corporate Summary
    • 10.21.3 Product Offerings for Global NIPT Market
    • 10.21.4 Financials
      • 10.21.4.1 Financial Summary
    • 10.21.5 SWOT Analysis

11 Report Scope and Methodology

  • 11.1 Scope of the Report
  • 11.2 Global NIPT Market Segmentation
  • 11.3 Research Methodology
    • 11.3.1 Primary Research
    • 11.3.2 Secondary Research
    • 11.3.3 Key Data Points from Primary Sources
    • 11.3.4 Key Data Points from Secondary Sources
    • 11.3.5 Data Triangulation
    • 11.3.6 Top-Down Approach (Segment Wise Analysis)
    • 11.3.7 Bottom-Up Approach (Segmental Analysis)
  • 11.4 Assumptions and Limitations
  • 11.5 Data and Prediction Modelling

I Annexure 1: Recent Key Developments (2014 - 2018)

II Annexure 2: Product Mapping

III Annexure 3: Patent Landscape

Back to Top